Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer

  • Authors:
    • Masashi Yahagi
    • Masashi Tsuruta
    • Hirotoshi Hasegawa
    • Koji Okabayashi
    • Yuko Kitagawa
  • View Affiliations

  • Published online on: March 1, 2017     https://doi.org/10.3892/mco.2017.1177
  • Pages: 529-533
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liver dysfunction that may affect drug metabolism is a major concern in patients treated with chemotherapy. Thus, assessment of the degree of liver dysfunction is crucial for predicting the adverse events of chemotherapy. The non‑alcoholic fatty liver disease fibrosis score (NFS) is a non‑invasive clinical scoring system constructed from routine clinical and laboratory variables. The aim of this study was to evaluate whether NFS was useful for predicting the adverse events of chemotherapy including irinotecan (CPT‑11) for colorectal cancer. Between January, 2007 and May, 2013, a total of 87 patients with unresectable/recurrent colorectal cancer who received first‑line chemotherapy including CPT‑11 were reviewed. Demographic variables, including pretreatment NFS, were retrospectively collected from medical records. The primary outcome was the association between pretreatment NFS and adverse events, such as hematological and non‑hematological toxicity, of chemotherapy including CPT‑11. The median pretreatment NFS was 1.302 (range, 5.158-2.620). Pretreatment NFS was an independent risk factor for hematological toxicity in a multivariate analysis (coefficient=0.932, 95% CI: 0.083‑1.781; P=0.031). Receiver operating characteristic curve analysis identified 0.347 as the optimal cut‑off value associated with hematological toxicity. Using this cut‑off, high NFS was found to be a significant risk factor for hematological toxicity (coefficient=2.019, 95% CI: 0.239‑3.798, P=0.026), but not for non‑hematological toxicity (P=0.546). Therefore, based on these results, NFS appears to be a significant predictor of hematological adverse events in chemotherapy including CPT‑11 for colorectal cancer and it is a non‑invasive, useful tool that may be used for determining regimens or doses of chemotherapy including CPT-11.
View Figures
View References

Related Articles

Journal Cover

April 2017
Volume 6 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yahagi, M., Tsuruta, M., Hasegawa, H., Okabayashi, K., & Kitagawa, Y. (2017). Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer. Molecular and Clinical Oncology, 6, 529-533. https://doi.org/10.3892/mco.2017.1177
MLA
Yahagi, M., Tsuruta, M., Hasegawa, H., Okabayashi, K., Kitagawa, Y."Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer". Molecular and Clinical Oncology 6.4 (2017): 529-533.
Chicago
Yahagi, M., Tsuruta, M., Hasegawa, H., Okabayashi, K., Kitagawa, Y."Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer". Molecular and Clinical Oncology 6, no. 4 (2017): 529-533. https://doi.org/10.3892/mco.2017.1177